Research & Development
First Patient Dosed in Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease
16 October 2020 - - US-based biopharmaceutical company Regulus Therapeutics Inc. (NASDAQ: RGLS) has initiated dosing in its Phase 1b clinical study of RGLS4326 in patients with ADPKD, the company said.

The Phase 1b is an adaptive design, open-label, multiple dose study in up to three cohorts of patients with ADPKD and will evaluate administration of RGLS4326 for safety, pharmacokinetics, and changes in levels of polycystin 1 and polycystin 2.

Patients with ADPKD, due to a mutation in the PKD genes, have been reported to have low levels of PC1 and PC2, the proteins encoded by the PKD1 and PKD2 genes, respectively.

This study is designed to assess whether different dose levels of RGLS4326 can increase levels of PC1 and PC2 in ADPKD patients.

The first cohort is expected to enroll up to nine patients who will receive RGLS4326 every two weeks over a six week period.

The company anticipates availability of results from the first cohort by the end of Q1 2021.

The company plans to use the data from this first cohort of patients with ADPKD, together with the data from the multiple ascending dose and the single ascending dose studies in healthy volunteers as well as the recently completed nonclinical studies, to obtain feedback from the US Food and Drug Administration on the acceptability of the company's approach to addressing the second set of FDA requirements to support studies of extended duration in patients.

ADPKD, caused by the mutations in the PKD1 or PKD2 genes, is among the most common human monogenic disorders and a leading cause of end-stage renal disease.

The disease is characterized by the development of multiple fluid filled cysts primarily in the kidneys, and to a lesser extent in the liver and other organs. Excessive kidney cyst cell proliferation, a central pathological feature, ultimately leads to end-stage renal disease in approximately 50% of ADPKD patients by age 60.

RGLS4326 is a novel oligonucleotide designed to inhibit miR-17 and designed to preferentially target the kidney.

Preclinical studies with RGLS4326 have demonstrated direct regulation of Pkd1 and Pkd2, reduction of cyst growth in human in vitro ADPKD models, and attenuation of cyst proliferation and improvement of kidney function in mouse models of ADPKD. 

The RGLS4326 IND is currently on a Partial Clinical Hold for treatment of extended duration by FDA until the second set of requirements outlined by the agency have been satisfactorily addressed.

Information from the Phase 1 clinical studies, together with information from the recently completed additional nonclinical studies, will be used to address the second set of requirements to support studies of extended duration.

RGLS4326 has received orphan drug designation from FDA in July 2020.

Regulus Therapeutics is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs.


Related Headlines